Bliss GVS Pharma Ltd
BLISSGVSBliss GVS Pharma Ltd
BLISSGVS
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 25.79 | 1.63 | 0.32% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.53 | 6.56 | 0.52% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Bliss GVS Pharma Limited is engaged in developing, manufacturing and marketing pharmaceutical formulations.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 571.24 | 810.94 | 841.18 | 936.20 | 728.50 | 597.43 | 778.94 | 769.38 | 798.98 | 820.36 | ||||||||||
Raw Materials | 262.55 | 368.69 | 391.70 | 618.79 | 435.67 | 341.59 | 420.18 | 374.38 | 390.46 | 681.51 | ||||||||||
| Power & Fuel Cost | 4.72 | 5.58 | 5.49 | 4.76 | 5.88 | 8.14 | 8.25 | 7.13 | 10.43 | |||||||||||
| Employee Cost | 33.74 | 61.35 | 69.23 | 42.32 | 53.69 | 68.09 | 76.15 | 86.17 | 95.58 | |||||||||||
| Selling & Administrative Expenses | 67.19 | 117.90 | 87.57 | 49.96 | 45.30 | 44.91 | 80.65 | 80.45 | 85.89 | |||||||||||
| Operating & Other expenses | 22.98 | 42.19 | 97.72 | 25.10 | 38.83 | 7.82 | 117.48 | 86.13 | 66.45 | |||||||||||
EBITDA | 180.06 | 215.23 | 189.47 | 195.27 | 149.13 | 126.88 | 76.23 | 135.12 | 150.17 | 138.85 | ||||||||||
| Depreciation/Amortization | 13.26 | 20.14 | 21.38 | 8.94 | 12.59 | 17.23 | 17.33 | 18.67 | 26.38 | 27.63 | ||||||||||
| PBIT | 166.80 | 195.09 | 168.09 | 186.33 | 136.54 | 109.65 | 58.90 | 116.45 | 123.79 | 111.22 | ||||||||||
| Interest & Other Items | 18.61 | 19.69 | 22.80 | 4.41 | 7.57 | 5.51 | 4.74 | 10.36 | 6.91 | 9.33 | ||||||||||
| PBT | 148.19 | 175.40 | 145.29 | 181.92 | 128.97 | 104.14 | 54.16 | 106.09 | 116.88 | 101.89 | ||||||||||
| Taxes & Other Items | 65.71 | 93.36 | 86.51 | 58.19 | 31.71 | 35.63 | 39.13 | 35.22 | 41.41 | 38.43 | ||||||||||
| Net Income | 82.48 | 82.04 | 58.78 | 123.73 | 97.26 | 68.51 | 15.03 | 70.87 | 75.47 | 63.46 | ||||||||||
| EPS | 8.00 | 7.95 | 5.70 | 12.00 | 9.43 | 6.64 | 1.45 | 6.82 | 7.23 | 6.06 | ||||||||||
| DPS | 0.50 | 0.60 | 1.00 | 1.00 | 0.50 | 0.50 | 0.50 | 0.50 | 0.50 | 0.50 | ||||||||||
| Payout ratio | 0.06 | 0.08 | 0.18 | 0.08 | 0.05 | 0.08 | 0.34 | 0.07 | 0.07 | 0.08 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Bliss GVS Pharma Ltd | 21.68 | 1.63 | 0.32% |
| Sun Pharmaceutical Industries Ltd | 45.35 | 6.47 | 0.75% |
| Cipla Ltd | 28.51 | 4.38 | 0.89% |
| Torrent Pharmaceuticals Ltd | 68.45 | 16.54 | 0.84% |
Price Comparison
Compare BLISSGVS with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Increased Total Retail Holding
In last 3 months, retail holding in the company has increased by 2.34%
Decreased Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has decreased by 1.12%
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 1 Mutual Funds holding Bliss GVS Pharma Ltd
| Funds (Top 1) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
Bandhan BSE Healthcare Index Fund Direct Plan-Growth Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.0009% | Percentage of the fund’s portfolio invested in the stock 0.08% | Change in the portfolio weight of the stock over the last 3 months 0.08% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 79/102 (+8) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividend Cuts
BLISSGVS has increased or maintained dividend levels over the last 5 years
Dividend Yield
Current dividend yield is 0.32%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹3.20 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateJul 18, 2024
Dividend/Share
₹0.50
Ex DateEx Date
Jul 18, 2024
Cash Dividend
Ex DateEx DateJul 12, 2023
Dividend/Share
₹0.50
Ex DateEx Date
Jul 12, 2023
Cash Dividend
Ex DateEx DateJun 20, 2022
Dividend/Share
₹0.50
Ex DateEx Date
Jun 20, 2022
Cash Dividend
Ex DateEx DateSep 13, 2021
Dividend/Share
₹0.50
Ex DateEx Date
Sep 13, 2021
Cash Dividend
Ex DateEx DateSep 17, 2020
Dividend/Share
₹0.50
Ex DateEx Date
Sep 17, 2020
Bliss GVS Pharma has allotted 34,250 equity shares under ESOP on 06 December 2024. With this allotment, the paid up equity share capital has increased to 10,53,66,272 equity shares of Re. 1/- each aggregating Rs. 10,53,66,272/-. Powered by Capital Market - Live
In a regulatory filing made on Saturday, the company informed that its manufacturing facilities located at Aliyali Village and Vevoor Village in Palghar district of Maharashtra has received a Certificate of GMP (good manufacturing practice) Compliance from the National Agency for Medicines and Medical Devices of Romania (NAMMDR). The compliance certificate has been granted following an EU GMP inspection that took place on 30th November and 1st December 2023 at the said facilities. Bliss develops and manufactures pharmaceutical formulations mainly for sale in Africa. The company sells formulations in the form of suppositories, pessaries, capsules, tablets, and syrups. It manufactures more than 250 branded formulations in the anti-malarial, anti-fungal, anti-bacterial, anti-biotic, anti-inflammatory, contraceptive, and anti-diabetic segments. Bliss also contract-manufactures suppositories and pessaries for Sun Pharma and Mankind. The company's consolidated net profit declined 42.66% to Rs 24.26 crore despite a 2.74% rise in net sales to Rs 217.68 crore in Q2 FY25 as compared with Q2 FY24. Powered by Capital Market - Live
Bliss GVS Pharma announced that the company's manufacturing facility situated at Plot No. 11, Dewan Udyog Nagar, Aliyali Village, Palghar, 401404, India and Survey No. 43-44, Vevoor Village, 401404, India, has successfully received a Certificate of GMP (Good Manufacturing Practice) Compliance from the National Agency for Medicines and Medical Devices of Romania (NAMMDR) following an EU GMP inspection that took place on 30 November and 1 December 2023. Powered by Capital Market - Live
Net profit of Bliss GVS Pharma declined 42.66% to Rs 24.26 crore in the quarter ended September 2024 as against Rs 42.31 crore during the previous quarter ended September 2023. Sales rose 2.74% to Rs 217.68 crore in the quarter ended September 2024 as against Rs 211.88 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales217.68211.88 3 OPM %19.0525.66 - PBDT42.6965.52 -35 PBT35.7159.13 -40 NP24.2642.31 -43 Powered by Capital Market - Live
Bliss GVS Pharma will hold a meeting of the Board of Directors of the Company on 24 October 2024.Powered by Capital Market - Live
Bliss GVS Pharma has allotted 157,550 equity shares under ESOP on 04 October 2024. With this allotment, the paid up equity share capital has increased to 10,53,02,022 equity shares of Re. 1/- each aggregating Rs. 10,53,02,022/-. Powered by Capital Market - Live
Bliss GVS Pharma will hold a meeting of the Board of Directors of the Company on 24 July 2024.Powered by Capital Market - Live
Bliss GVS Pharma declines after Palghar units gets Form 483 with 3 observations from US FDA
Bliss GVS Pharma share price falls on observations from USFDA
MRO-TEK Realty Ltd leads gainers in ‘B’ group
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of -3.12%, vs industry avg of 9.03%
Decreasing Market Share
Over the last 5 years, market share decreased from 0.43% to 0.21%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of -9.41%, vs industry avg of 15.27%